Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
13 studies found for:    E2609
Show Display Options
Rank Status Study
1 Completed An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects
Condition: Metabolism and Elimination
Intervention: Drug: E2609
2 Completed A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
Condition: Early Alzheimer's Disease
Intervention: Drug: E2609
3 Completed Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects
Condition: Healthy
Interventions: Drug: E2609;   Drug: Placebo
4 Completed Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects
Condition: Healthy Participants
Interventions: Drug: E2609;   Drug: Placebo
5 Completed Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects
Condition: Healthy Subjects
Interventions: Drug: E2609;   Drug: Placebo
6 Completed Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
Condition: Alzheimer's Disease
Interventions: Drug: E2609;   Drug: Placebo for E2609
7 Completed An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption
Condition: Alzheimer's Disease
Intervention: Drug: E2609
8 Recruiting A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease_
Condition: Alzheimer's Disease
Interventions: Drug: elenbecestat (E2609);   Drug: Placebo
9 Recruiting A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: elenbecestat (E2609);   Drug: Placebo
10 Completed Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort
Condition: Alzheimer's Disease
Interventions: Drug: Drug: E2609;   Drug: Placebo
11 Active, not recruiting Dose-Finding Study To Evaluate the Safety and Tolerability of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
Conditions: Alzheimer Disease;   Dementia, Alzheimer Type
Interventions: Drug: elenbecestat (E2609);   Drug: Placebo
12 Completed A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects
Condition: Healthy Subjects
Interventions: Drug: Placebo;   Drug: E2609;   Drug: Moxifloxacin
13 Completed A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil
Condition: Healthy Subjects
Interventions: Drug: E2609;   Drug: itraconazole;   Drug: rifampin;   Drug: digoxin;   Drug: donepezil

Study has passed its completion date and status has not been verified in more than two years.